Banca de QUALIFICAÇÃO: RENATO FERREIRA DE ALMEIDA JUNIOR

Uma banca de QUALIFICAÇÃO de DOUTORADO foi cadastrada pelo programa.
DISCENTE : RENATO FERREIRA DE ALMEIDA JUNIOR
DATA : 26/09/2019
HORA: 08:00
LOCAL: Sala Rute - HUOL
TÍTULO:

Chloroquine Nanoparticles in Type 1 Diabetes Mellitus: A New
Immunomodulatory Therapy

PALAVRAS-CHAVES:

Chloroquine, diabetes, immunity, nanoparticles, cytokines

PÁGINAS: 25
GRANDE ÁREA: Ciências da Saúde
ÁREA: Farmácia
RESUMO:

Background: Inflammation induced by type 1 Diabetes mellitus (T1DM), contribute
to the development of micro and macrovascular complications. In this context,
chloroquine (CQ) an anti-inflammatory emerges as an adjunctive treatment to insulin.
In addition, the use of this drug incorporated in nanoparticles will increase its
bioavailability, improving the pharmacological response. To evaluate the effect of CQ
and nanoparticle-incorporated chloroquine (CQNP) on cytokines proinflammatory
mRNA expressions in peripheral blood mononuclear cells (PBMCs).
Patients and methods: CQNP were fabricated by emulsification-solvent evaporation
method and evaluated in vitro via measuring particle size and stability. Twenty-five
patients with T1DM aged 10-16 years, were recruited, in the pediatric endocrinology
unit of a University Hospital. PBMCs were isolated from all individuals and then cells
were plated. Cytotoxicity test was performed to assess which drug concentration
would be used. After choosing the ideal CQ concentration, the PBMCs were tested
for 24 and 48 hours (h), and submitted to 3 different conditions: without treatment,

treatment with CQ, and treatment with CQNP. In the end of each period, mRNA
expressions of IL1B, IFNG, TNFA, IL12 and IL10 were determined by relative
quantification in real time PCR.
Results: The formulation was obtained physicochemical properties of NP small
(<200 nm) with a narrow size distribution (PdI < 0.33) with negative zeta potential (27
mV). IL1B (after treatment with CQ for 24 and 48h; and treatment with CQNP for
24h), IFNG (after treatment with CQ and CQNPs for 24 and 48h), TNFA (after
treatment with CQ and CQNPs for 48h), IL12 (after treatment with CQ and CQNP for
24 and 48h) and IL10 (after treatment with CQ and CQNPs for 24h) mRNA
expressions were significantly reduced in the cells treated when compared to the
untreated.
Conclusion: This study shows the reduction of expression of cytokines
inflammatory, demonstrating that CQ reduces inflammation. These results open
perspectives of the adjuvant therapeutic effect of CQ in T1DM.

MEMBROS DA BANCA:
Presidente - 2323511 - ADRIANA AUGUSTO DE REZENDE
Externo ao Programa - 2275890 - MARCELO DE SOUSA DA SILVA
Externo à Instituição - MARCOS FELIPE DE OLIVEIRA GALVÃO - NENHUMA
Externa à Instituição - RAQUEL DE MELO BARBOSA - F.M.Nassau